https://www.selleckchem.com/products/pfi-2.html
001 and .01 respectively). NAC treatment significantly reduced 14- and 28-day mortality in patients with severe disease ( .001, respectively). NAC improved over time the PO2/FiO2 ratio and decreased the white blood cell, CRP, D-dimers and LDH levels. In the multivariable logistic regression analysis, non-severe illness and NAC administration were independent predictors of 28-days survival. Oral NAC administration (1200 mg/d) in patients with COVID-19 pneumonia reduces the risk for mechanical ventilation and mortality. Our find
Like
Comment
Share
